![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Discontinue Falk Phase 2 Trial of TSO in Crohn's Disease
November 07, 2013 06:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
November 06, 2013 06:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2013
November 01, 2013 08:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Announces Top-Line Results From Its TRUST-I Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease
October 14, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Announces Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis
September 12, 2013 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences
September 03, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Participate in Citi's 8th Annual Biotech Conference
August 27, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Present at the Upcoming Themes in Helminth Biology Scientific Conference
August 20, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 20, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2013
August 05, 2013 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences
August 01, 2013 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...